Robert W. Baird Boosts Illumina (NASDAQ:ILMN) Price Target to $128.00

Illumina (NASDAQ:ILMN) had its price objective lifted by Robert W. Baird from $125.00 to $128.00 in a report released on Friday morning, Benzinga reports. They currently have a neutral rating on the life sciences company’s stock.

Other equities analysts also recently issued research reports about the company. Royal Bank of Canada reiterated an outperform rating and issued a $253.00 price objective on shares of Illumina in a report on Tuesday, April 9th. TD Cowen cut shares of Illumina from an outperform rating to a market perform rating and set a $144.00 price target for the company. in a research report on Thursday, January 4th. Stephens restated an overweight rating and issued a $170.00 price objective on shares of Illumina in a report on Wednesday, April 10th. HSBC lowered shares of Illumina from a buy rating to a hold rating in a report on Tuesday, January 16th. Finally, Barclays upped their price target on Illumina from $85.00 to $100.00 and gave the stock an underweight rating in a research note on Wednesday, April 10th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, Illumina has a consensus rating of Hold and an average target price of $164.65.

Illumina Trading Up 0.9 %

Shares of ILMN opened at $118.98 on Friday. Illumina has a 1-year low of $89.00 and a 1-year high of $213.91. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26. The firm’s 50-day moving average price is $129.67 and its 200-day moving average price is $127.00. The firm has a market capitalization of $18.95 billion, a price-to-earnings ratio of -14.60 and a beta of 1.20.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.05. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The business had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.05 billion. During the same period in the previous year, the firm posted $0.08 EPS. The business’s revenue was down 1.0% on a year-over-year basis. Sell-side analysts anticipate that Illumina will post 0.91 EPS for the current year.

Insider Buying and Selling

In other news, CEO Jacob Thaysen bought 7,330 shares of the company’s stock in a transaction on Thursday, February 22nd. The shares were acquired at an average cost of $135.29 per share, with a total value of $991,675.70. Following the completion of the transaction, the chief executive officer now owns 14,861 shares of the company’s stock, valued at approximately $2,010,544.69. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.17% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Trivant Custom Portfolio Group LLC grew its holdings in Illumina by 166.7% during the first quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock valued at $27,000 after purchasing an additional 125 shares during the period. Annis Gardner Whiting Capital Advisors LLC purchased a new position in shares of Illumina during the 3rd quarter valued at about $30,000. VisionPoint Advisory Group LLC grew its stake in shares of Illumina by 344.6% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock valued at $34,000 after acquiring an additional 193 shares during the period. Wetzel Investment Advisors Inc. purchased a new stake in Illumina in the 4th quarter worth approximately $37,000. Finally, Massmutual Trust Co. FSB ADV raised its stake in Illumina by 86.8% during the 1st quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company’s stock worth $39,000 after acquiring an additional 132 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.